![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
REAL-WORLD PERSISTENCY OF PATIENTS RECEIVING TENOFOVIR-BASED PRE-EXPOSURE PROPHYLAXIS FOR THE PREVENTION OF HIV INFECTION IN THE US
|
|
|
Alan Oglesby,1 Guillaume Germain,2 François Laliberté,2 Staci Bush,1 Heidi Swygard,1 Sean MacKnight,2 Annalise Hilts,2 Mei S. Duh3
1ViiV Healthcare, Research Triangle Park, NC, USA; 2Groupe d'analyse, Ltée, Montréal, Québec, Canada; 3Analysis Group, Inc, Boston, MA
![1001211](../images/100121/100121-6/1001211.gif)
![1001212](../images/100121/100121-6/1001212.gif)
![1001213](../images/100121/100121-6/1001213.gif)
![1001214copy](../images/100121/100121-6/1001214copy.gif)
![1001215](../images/100121/100121-6/1001215.gif)
![1001216](../images/100121/100121-6/1001216.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|